Variability in the measurement of activated clotting time depending on the type of cuvette used Abstract
Section: Artículos Científicos
Authors
Damián Lorenzo García1, Teresa Rodríguez Benítez1, Patricia Calderín Escobio1, Efrén Pérez García1, Pablo Benítez Martín1, José Miguel Latorre Jiménez1, José Manuel Álvarez Vázquez1, Manuel Benito Mayoral1, Vicente Rubio Alcañiz2
Contact address
Vicente Rubio Alcañiz. C/ Lomo La Plana, 33 2 C. 35019 Las Palmas de Gran Canaria
Contact email: v.rubio@celp.es
Abstract
Introduction. Activated clotting time (ACT) is a widely used test to adjust the heparin dose in interventional procedures. Achieving the therapeutic range is essential to avoid bleeding or thrombosis complications. In our hemodynamic laboratory, the ACT measurement system has been changed and, following the supplier‘s recommendation, only the ACT+ cuvette was used, although there were two cuvettes available. Following this change, patients unexpectedly required higher doses of heparin to reach the therapeutic range. Our objective was to find out which of the two cuvettes offers a more reliable ACT result for cardiac intervention.
Method. In May 2020, 71 blood samples corresponding to 34 patients undergoing cardiac catheterization in the hemodynamic unit were prospectively analysed and compared. The ACT of each sample was measured using the 2 cuvettes. The results were analysed using the Student‘s t test, the Interclass correlation coefficient and the Bland-Altman analysis.
Results. The mean age was 6615 years, 70% of patients were men and 87.3% of the measurements corresponded to systemic anticoagulation. The mean ACT obtained with the ACT+ cuvette was 21558 seconds and that of the ACT-LR was 29369 seconds
(p <0.001). The correlation coefficient was positive (r =0.940). However, with the Bland Altman method, the mean bias between the two cuvettes was -7830 seconds.
Conclusions. The ACT-LR cuvette was more sensitive and patients achieved therapeutic range ACT with lower doses of heparin.
Keywords:
blood coagulation tests; anticoagulants; safety; cardiac catheterization; point-of-care systems
Versión en Español
Título:
Variabilidad en la medición del tiempo de coagulación activado según el tipo de cubeta utilizada
Artículo completo no disponible en este idioma / Full article is not available in this language
Bibliography
1. Alfaro-Lara ER, Atención al paciente con enfermedades cardiovasculares. Sociedad Española de Farmacia Hospitalaria. Curso 2012. (Consultado el 20/02/2020). Disponible en: http://formacion.sefh.es/dpc/framework/atf-cardiovasculares/paciente-tromboembolismo-venoso/tema01_menu06_submenu01_diapo01.php
2. Sierra-Hernández CE, Barroso-Morales ML, Rodríguez-Hernández RN, Samarín-Fernández G. Anticoagulantes: Heparina no fraccionada, protamina, heparina de bajo peso molecular y bivalirudina. En Fernández Maese JM, García Aranda FJ, Gómez Fernández M, Ramírez Yáñez P, Rodríguez García-Abad, Sánchez Hernández EM, Seoane Bello M. Manual de Procedimientos de enfermería en Hemodinámica y cardiología intervencionista. 2ª ed. Madrid: Asociación Española de Enfermería en Cardiología; 2014.p 528-33.
3. Accriva Diagnostics Hemochron Signature Elite Brochure. 2017. (Consultado el 10/03/2020). Disponible en:
http://www.medwrench.com/documents/view/9122/accriva-diagnostics-hemochron-signature-elite-brochure
4. Grodsky MJ. Transitioning from the Hemochron Response to the Hemochron Signature Elite. 2016. (Consultado el 13/03/20). Disponible en:
http://youtube.com/watch?v=nBGCSH6Z7Cc
5. Wehner JE, Boehne M, David S, Brand K, Tiede A, Bikker R. Activated clotting time (ACT) for monitoring of low-dose heparine: performance characteristics in healthy adults and critically ill patients. Clin Appl Thromb Hemost. 2020;26:1-9.
6. Matte GS, Howe RJ, Ibla J, Emani S, Emani SM. Transition from Hemochron Response to Hemochron Signature Elite activated clotting time devices in a congenital cardiac surgery practice. J Extra Corpor Technol. 2019;51:221-6
7. Nilsson S, Appelblad M, Svenmarker S. Can we rely on the activated clotting time to measure heparin anticoagulation? A clinical evaluation of two ACT monitors. J Extra Corpor Technol. 2020;52:212-7.
8. Dirkmann D, Nagy E, Britten MW, Peters J. Point-of-care measurement of activated clotting time for cardiac surgery as measured by the Hemochron signature elite and the Abbott i-STAT: agreement, concordance, and clinical reliability. BMC Anesthesiol. 2019;19:174.
9. Zamudio-Godínez L. Cálculos del volumen sanguíneo. Rev Mex Med Tran. 2017;10:14-17
10. Hemochron Signature Elite Low Range Activated Clotting Time (ACT-LR). 2015. (Consultado el 13/04/2020). Disponible en:
www.sfgh-poct.org/wp-content/uploads/2015/04/ACT-Training-SFHN-Version.pdf
11. Ojito JW, Hannan RL, Burgos MM, Lim H, Huynh M, Velis E et al. Comparision of point-of-care activated clotting time systems utilized in a single pediatric institution. J Extra Corpor Technol. 2012; 44(1): 15-20.
12. Senzel L, Fiorella D, Woo H, Gasoarus A, Bock JL. Relationship of activated clotting time to heparin dose depends on the type of cuvette used with the Hemochron Signature Elite. Point of Care: the journal of near-patient testing and technology. 2013; 12:150-2.
